Key terms

About BRTX

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BRTX news

Yesterday 2:15pm ET Buy Rating on BioRestorative Therapies for Innovative Obesity Treatment Approach May 08 7:41am ET BioRestorative develops new therapeutic candidate using ThermoStem platform May 02 12:15pm ET Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunities May 02 12:10pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX) Apr 30 7:40am ET BioRestorative Therapies announces commercial agreement with Cartessa Apr 17 4:05pm ET Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances Apr 16 11:31am ET BioRestorative’s BRTX-100 trial to use sham injection control, says Roth MKM Apr 16 7:50am ET BioRestorative announces FDA clearance of Phase 2 BRTX-100 study protocol Apr 08 7:47am ET BioRestorative partners with Galen Patient Recruitment for BRTX-100 trial Apr 03 4:39pm ET BioRestorative Therapies files registration statement of Form S-1 Apr 03 4:20pm ET BioRestorative Therapies files to sell 2.51M shares of common stock for holders Mar 12 7:42am ET BioRestorative Therapies Clarifies Disclosure Regulations Impact Feb 09 4:38am ET BioRestorative Therapies Sparks Investor Interest with New Transaction Feb 09 4:38am ET BioRestorative Therapies Secures $8.1M Through Warrant Restructuring

BRTX Financials

1-year income & revenue

Key terms

BRTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BRTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms